Park Ha Biological Technology is trading at $0.63 (-5.43%) in pre-market, extending a sharp decline following a recent capital raise. - The company closed a $2.0 million registered direct offering on June 15, 2026, contributing to ongoing dilution concerns and selling pressure. - Shares fell 9.03% on July 9, marking several consecutive sessions of selling pressure. - This selloff occurs amidst recent news of a new AI beauty pact and North American Amazon store approvals.